News

News

Interview with President/CEO Cho Wook-Je “Yuhan Corporation – To become one of the top 50 global pharmaceutical companies within 5 years”

Yuhan Corporation has prepared a blueprint to double their sales and become one of the world's top 50 pharmaceutical companies by 2026, the year they will be celebrating the 100th ...
Read More

[Job Opening] Business Development Manager – San Diego & Boston

Yuhan USA Corporation was established in January 2018 as a wholly-owned subsidiary of Yuhan Corporation, Korea’s largest pharmaceutical company with a 95-year heritage. As an outpost of Yuhan’s globalization strategy, ...
Read More

Yuhan Corporation ranked 1st in the pharmaceutical category of the Most Admired Company for 18 consecutive years

Yuhan Corporation was ranked as the 1st in the pharmaceutical industry and 4th in overall in the 2021 Korea's Most Admired Company Award held by the Korea Management Association. Yuhan ...
Read More

Yuhan Corporation’s Investments of 224 Million Dollars in over 6 Years Results in Great R&D and Sales Performance

Yuhan Corporation is strengthening its open innovation by expanding investments in biotech companies and research institutes with different areas of focus. Using their financial resources to the full extent, the ...
Read More

Yuhan Corporation, Largest Investment in R&D Leading to Achievements in New Drug Development

Yuhan Corporation invested more than 179 million dollars in their R&D in 2020, one of the largest among the traditional pharmaceutical companies in South Korea. Yuhan has been maintaining the ...
Read More

Yuhan’s NSCLC treatment “Leclaza” approved as South Korea’s 31st novel drug

Yuhan Corporation’s “Leclaza (Ingredient: Lazertinib)”, a third-generation targeted therapy for EGFR T790M-mutated NSCLC, has received approval as a 2nd line of therapy from the South Korean Ministry of Food and ...
Read More

Yuhan to Receive $65m from Janssen for Milestone Achievement of Lazertinib

Yuhan Corporation announced that the company will receive $65 million in milestone payment from Janssen Biotech for Lazertinib, a third-generation EGFR TKI for NSCLC (non-small cell lung cancer), which was ...
Read More

Yuhan Corporation signs an MOU with Imperial College London

Yuhan Corporation has signed a memorandum of understanding for strategic alliance with Imperial College London to participate in the “ICiC (Imperial Confidence in Concept)” program and fund their proof of ...
Read More

Yuhan announced a neurodegenerative disease Research & BD alliance with a leading university and biotech company in Korea

Yuhan Corporation has signed a three-party agreement with Sungkyunkwan University (SKKU) and Imnewrun Biosciences to build a Brain Disease R&BD ecosystem. For the first time in Korea, a pharmaceutical company, ...
Read More

Yuhan to license out a gastrointestinal drug candidate to Processa for $415 million

Yuhan Corporation entered into a licensing agreement worth up to $415 million with Processa Pharmaceuticals for the development of YH12852, a small molecule drug in development for the treatment of ...
Read More

Yuhan-AbClon now in the race for a COVID-19 therapeutic antibody

Yuhan and AbClon have joined the list of pharmaceutical companies that are in the race to develop a therapeutic antibody for COVID-19. They have identified a multifariously adaptive candidate for ...
Read More

Yuhan expands its allergy treatment pipeline with the in-license of GI-301 from GI Innovation

Yuhan Corporation has in-licensed GI Innovation's allergy treatment pipeline (GI-301) from GI Innovation in a deal that could potentially total $1.2 billion. Yuhan and GI Innovation’s collaboration to develop next-generation ...
Read More

Yuhan Corporation to recoup KRW 200 billion investment in five years

Yuhan Corporation's global R&D and open innovation strategy - in which they introduce early assets from the startups, conduct preclinical & early clinical studies, then license them out to the ...
Read More

J&J’s Experimental Lung Cancer Drug Receives Breakthrough Therapy Designation

Here’s an update from our business partner Janssen Biotech that JNJ-6372 in combination with Lazertinib (YH25448), a novel third-generation EGFR TKI for advanced NSCLC that Yuhan Corporation out-licensed to them ...
Read More

Yuhan to invest 14% of its sales in R&D this year for “Lazertinib’s Phase-3 trial & Global Open Innovation

In 2020, Yuhan Corporation is going to invest the largest amount in history for its R&D program to speed up the development of Lazertinib (YH25448) – the first-line treatment for ...
Read More

Yuhan USA’s 2019 Recap

With 2020 just around the corner, let's take a look back at our 2019! It has been a wonderful year for us here at Yuhan USA and may the next ...
Read More